<DOC>
	<DOCNO>NCT00530881</DOCNO>
	<brief_summary>This 4-week , multicenter , randomize , double-blind , parallel group , placebo-controlled , safety , tolerability , efficacy study . Patients screen one three dos PHX1149 ( new drug candidate treatment Type 2 diabetes ) placebo . The drug `` DPP4 inhibitor ''</brief_summary>
	<brief_title>Randomized , Double-Blind , Placebo-Controlled , With PHX1149 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus treatment metformin +/ TZD Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>